Skip to main content

Advertisement

Table 4 Summary of median and 1–3–5 years actuarial data for overall survival and progression free survival for the 3DCRT and VMAT cohorts

From: Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy

  Median time [years] p 1-year 3-years 5-years
Progression free survival
 3DCRT 0.99 ± 0.07 (CI95:range 0.9–1.1) 0.02 49.6 ± 4 % 19.1 ± 3.1 % 11.2 ± 2.5 %
 VMAT 1.29 ± 0.13 (CI95:range 1.01–1.5) 60.8 ± 3.8 % 29.7 ± 4.6 % 29.7 ± 4.6 %
Overall survival
 3DCRT 1.21 ± 0.09 (CI95:1.03–1.3) <0.01 63.3 ± 3.8 % 21.5 ± 3.3 % 10.6 ± 2.5 %
 VMAT 1.56 ± 0.09 (CI95:1.37–1.74) 73.4 ± 3.5 % 30 ± 4.6 % 24.2 ± 5.4 %